本报北京电（记者陈静文）近日，清华大学北京清华长庚医院（以下简称"清华长庚"）在建院11周年之 际召开临床医学科技创新大会，发布清华大学临床医学科技创新平台落成并正式启用。 该平台整合了清华大学临床生物样本资源中心、临床药械试验中心、临床转化医学中心、医学数据科学 中心、健康科技研发中心、临床研究中心6大核心实体，构建起覆盖"临床研究—临床转化—药械研发— 数据科学—医工结合—临床验证"全链条的协同创新体系，实现了各实体与环节之间的资源互通、能力 互补、相互支撑。 "清华大学临床医学科技创新肩负3大使命，即打造协同创新枢纽平台，培育医工融合领军团队，驱动智 慧医疗转化应用。"清华长庚医院院长董家鸿院士说，具有医工融合特色的医疗研究中心，将加速新技 术从实验室到临床的转化进程，让更多创新成果惠及百姓健康。 活动现场，创新网络持续织密：清华长庚牵头成立综合研联体，联动多家医疗机构共享资源、开展交流 培训和高水平临床研究；推进医校联动，清华长庚与清华大学生物医学工程学院、膜生物学全国重点实 验室达成战略合作，"昌平区高校科研平台延伸基地"正式落户清华长庚；推动医企研发，清华长庚与多 家医疗科技企业签约合作。 创新成 ...

12月8日，国内首个脑转移瘤精准放疗IIT研究，首都医科大学宣武医院ZAP-X IIT研究启动仪式顺利召 开。该临床研究(Investigator Initiated Trial，简称IIT)由宣武医院与百洋医药（301015.SZ）合作开展，宣 武医院神经外科主任张鸿祺担任主要研究者（PI），旨在进一步探索全球领先的脑肿瘤精准放疗设备 ——ZAP-X放射外科机器人在脑转移瘤患者中的临床疗效与安全性、剂量学特征。 ...

Core Insights - Breast cancer is the most prevalent cancer among women globally, with nearly 70% of patients diagnosed with luminal-type breast cancer [1] - Chinese medical experts have utilized an AI model to identify precise treatment targets for immune-regulatory and RTK-driven luminal-type breast cancer patients, significantly improving treatment efficacy [1] Group 1: Research Findings - The research led by Professor Shao Zhimin was published in the renowned journal "Cancer Cell" and categorized luminal-type breast cancer into four subtypes: classic luminal (SNF1), immune-regulatory (SNF2), proliferative (SNF3), and RTK-driven (SNF4) [1] - The study, named LINUX, is a multi-center, randomized, controlled Phase II clinical trial focusing on treatment challenges for advanced luminal-type breast cancer patients who have developed resistance [1] Group 2: AI Model Application - The AI molecular model, described as a "super brain," integrates vast amounts of microscopic information and can produce molecular typing results within five minutes, significantly lowering the barriers and costs for precision diagnosis [2] - The clinical research demonstrated that for immune-regulatory and RTK-driven luminal-type breast cancer patients, different precision treatment strategies increased objective response rates from 30% to 65% and from 20% to 70%, respectively, with median progression-free survival more than doubling for both subtypes [2] Group 3: Future Plans - The research team plans to conduct a multi-center, randomized controlled Phase III clinical trial targeting precision treatment strategies for immune-regulatory (SNF2) and RTK-driven (SNF4) patients to validate their effectiveness and superiority in a larger patient population [2]

Core Insights - The "Health China 2030" plan highlights diabetes as a key chronic disease for prevention and treatment, with Diabetic Macular Edema (DME) identified as a significant challenge in eye disease management [1][4] - A new research initiative, the "DME Disease Diagnosis and Treatment Insight Research Project," will be launched on World Diabetes Day 2025 to analyze the current treatment landscape for DME in China [1][4] Group 1: Project Overview - The project aims to shift the treatment paradigm for DME from short-term fluid control to long-term disease management, focusing on recurrence risk and treatment expectations [4] - The initiative will involve a nationwide survey targeting over a thousand doctors from tertiary and secondary hospitals, collecting data on DME recurrence risk factors and long-term treatment needs [4][5] Group 2: Goals and Methodology - The project will utilize standardized questionnaires to gather insights from clinical practices, aiming to enhance communication between doctors and patients and develop more effective treatment pathways [4][5] - A comprehensive "DME Disease Diagnosis and Treatment Research White Paper" will be produced, disseminating findings to raise awareness about long-term management strategies for DME [5]

Core Insights - The "Second International Breast Cancer Research Forum" hosted by Shandong University Qilu Second Hospital focused on breast cancer research, clinical diagnosis, and precision prevention strategies, featuring over 20 expert presentations from 12 countries and regions [1][2][7] Group 1: Event Overview - The forum aimed to create a high-level academic exchange platform addressing key areas in breast cancer research, including clinical diagnosis and innovative treatment methods [1] - Key figures from Shandong University and international experts participated, emphasizing the importance of global collaboration in breast cancer prevention and treatment [2] Group 2: Institutional Goals and Achievements - Shandong University Qilu Second Hospital is transitioning from a disease-centered approach to a health-centered strategy, focusing on medical innovation, talent cultivation, and research成果转化 [1][2] - The hospital showcased its achievements in breast cancer cohort construction, biobank standardization, and digital medicine platform development [2] Group 3: Academic Contributions - The forum featured presentations on various topics, including molecular pathology, treatment innovations, and AI-assisted medical imaging, highlighting the comprehensive nature of breast cancer research [3][4][5][6] - Notable presentations included discussions on the Hippo signaling pathway, metabolic vulnerabilities in luminal breast cancer, and advancements in cell and gene therapy for endocrine diseases [3][4][5] Group 4: Future Directions - The collaboration between the forum and the inaugural editorial board meeting of "Molecular and Digital Medicine" aims to enhance interdisciplinary integration and accelerate the translation of research成果 into clinical practice [7]

Core Insights - The newly elected academicians from the Chinese Academy of Sciences and the Chinese Academy of Engineering highlight a concentration in the field of oncology and major diseases, with a total of 73 and 71 academicians elected respectively [1][3]. Group 1: Elected Academicians - Among the newly elected academicians, notable experts in clinical medicine include Zhou Jian from Zhongshan Hospital affiliated with Fudan University and Fang Jingyuan from Renji Hospital affiliated with Shanghai Jiao Tong University [1]. - Other elected academicians in clinical medicine include Cai Xiujun from Shao Yifu Hospital affiliated with Zhejiang University and Wang Yongjun from Beijing Tiantan Hospital affiliated with Capital Medical University [1]. Group 2: Focus on Liver Cancer - Zhou Jian specializes in clinical and basic research on liver cancer and has received the National Science and Technology Progress Award five times; he emphasizes that liver cancer can be managed as a chronic disease [3]. - Zhou Jian and Fang Jingyuan published a significant report in The Lancet, indicating that at least 60% of liver cancer cases are preventable by reducing risk factors such as viral hepatitis and alcohol consumption [3]. - A miRNA early diagnosis model for liver cancer developed by Zhou Jian and Fang Jingyuan has been successfully transformed into a clinical application, with over 5 million tests conducted, significantly improving early detection rates compared to traditional markers [3]. Group 3: Focus on Gastrointestinal Cancer - Fang Jingyuan has made significant contributions in the field of gastrointestinal cancer, particularly in early warning, diagnosis, prevention, and comprehensive treatment [4]. - Fang Jingyuan has innovatively analyzed gut microbiota to assess the effectiveness of postoperative chemotherapy and immunotherapy for colorectal cancer [4].

Core Insights - Obesity is a significant global public health issue, with a retrospective study revealing a 69.5% incidence of weight regain among patients who underwent sleeve gastrectomy (SG) [6][7] - The study identifies the third year post-surgery as a critical period for weight rebound, with 41.7% of patients experiencing a weight regain of 20% or more of their maximum weight loss, meeting the criteria for weight regain (WR) [6][7][8] Study Overview - The research included 676 patients who underwent SG at Shanghai Jiao Tong University from January 2011 to June 2022, with a median follow-up of three years [6][7] - Factors associated with higher postoperative total weight loss percentage (%TWL) included baseline age, initial BMI, male gender, and absence of hypertension [7] - Among 540 patients with complete follow-up at 1, 3, and 5 years, the rate of weight regain increased from 21.7% at year three to 32.6% at year five [7] Weight Change Patterns - Patients were categorized into three groups based on weight change trajectories: significant weight loss, moderate weight loss, and minimal weight loss [7] - The significant weight loss group had higher baseline BMI, waist circumference, fasting insulin, and insulin resistance index (HOMA-IR) compared to the minimal weight loss group [7] Implications for Future Research - The findings provide a scientific basis for identifying high-risk patients and developing preventive strategies against weight regain after SG [8]

Core Viewpoint - A special collection on epidemiological research titled "Advancing China and International Cohort Studies" was recently released at the First Hospital of Jilin University in Changchun, where researchers from multiple countries gathered to discuss issues related to large-scale cohort studies [3]. Group 1 - The event highlighted the importance of international collaboration in epidemiological research [3]. - Researchers focused on addressing challenges and opportunities in conducting large-scale cohort studies [3].

Core Insights - The establishment of the first clinical research center for brain-machine interfaces in Shanxi marks a significant advancement in the treatment of difficult-to-treat neurological conditions, with the potential to benefit many patients [1][2] - The center will focus on innovative treatments such as deep brain stimulation (DBS) and intelligent perceivable brain pacemakers, which can adjust brain function and collect brain electrical signals [1][2] Group 1 - The first patient, Ms. Zhao, experienced significant improvement in her condition after undergoing DBS, highlighting the potential of this technology for patients with severe obsessive-compulsive disorder [1] - The center is equipped with advanced facilities, including a composite operating room and intelligent surgical robots, to support its multidisciplinary approach [2] - The center aims to collaborate with universities and enterprises to explore applications of brain-machine interfaces in various neurological disorders, including epilepsy, Parkinson's disease, dementia, and obsessive-compulsive disorder [2] Group 2 - The center's multidisciplinary team includes specialists from neurosurgery, neurology, mental health, rehabilitation medicine, and medical imaging, enhancing the scope of treatment options available [2] - Future plans include using neurostimulation techniques to aid in the recovery of patients with consciousness disorders, such as those in a vegetative state [2] - The innovative approach of the center represents a shift towards personalized treatment pathways for patients with neurological conditions [1][2]

Core Viewpoint - The recent research from the University of California, Berkeley, challenges the traditional belief that high-calorie foods are the main cause of obesity, suggesting that the pleasure derived from eating can play a positive role in weight management [4][7]. Group 1: Research Findings - The study titled "Changes in neurotensin signalling drive hedonic devaluation in obesity" reveals that the enjoyment of food can help maintain energy balance, redefining the relationship between food pleasure and obesity [4][7]. - High-fat diets were shown to impair the brain's reward system, leading to reduced appetite for high-calorie foods in obese mice, despite weight gain [9][11]. - The research identified neurotensin (NTS) as a key player in this process, with high-fat diets significantly suppressing NTS expression, which is crucial for enhancing dopamine neuron activity during food enjoyment [11][12]. Group 2: Implications for Weight Management - Restoring NTS levels through dietary intervention or gene therapy resulted in obese mice regaining normal food responses, reducing overall food intake, and improving anxiety symptoms [12]. - The findings suggest a shift from traditional weight loss strategies focused on appetite suppression to approaches that enhance the brain's reward mechanisms related to food enjoyment, potentially leading to the development of "happy dieting" therapies [12]. - This research opens new avenues for addressing obesity and related metabolic disorders, emphasizing the intersection of neuroscience and nutrition [12].